EX-99.2 3 ef20017972_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2
INF904: TOPLINE RESULTS FROM PHASE I MAD STUDY January 4, 2024

Important Notice and Disclaimer This presentation has been prepared by InflaRx N.V. (“InflaRx” or the “Company”). This presentation is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. This presentation may not be relied upon in connection with the purchase or sale of any security and should not be construed as investment advice. Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the receptiveness of Gohibic (vilobelimab) as a treatment for COVID-19 by COVID-19 patients and U.S. hospitals and related treatment recommendations by medical/healthcare institutes and other third-party organizations, our ability to successfully commercialize and the receptiveness of Gohibic (vilobelimab) as a treatment for COVID-19 by COVID-19 patients and U.S. hospitals or our other product candidates; our expectations regarding the size of the patient populations for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and clinical utility of Gohibic (vilobelimab) in its approved or authorized indication or for vilobelimab and any other product candidates, under an Emergency Use Authorization and in the future if approved for commercial use in the United States or elsewhere; the success of our future clinical trials for vilobelimab’s treatment of COVID-19 and other debilitating or life-threatening inflammatory indications, including pyoderma gangrenosum, and any other product candidates, including INF904, and whether such clinical results will reflect results seen in previously conducted pre-clinical studies and clinical trials; the timing, progress and results of pre-clinical studies and clinical trials of our product candidates and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, the costs of such trials and our research and development programs generally; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways, including related to our Marketing Authorization Application submission for vilobelimab and our biologics license application submission for Gohibic (vilobelimab), and our ability to obtain and maintain full regulatory approval of vilobelimab or Gohibic (vilobelimab) for any indication; whether the U.S. Food and Drug Administration, the European Medicines Agency or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; our expectations regarding the scope of any approved indication for vilobelimab; our ability to leverage our proprietary anti-C5a and C5aR technologies to discover and develop therapies to treat complement-mediated autoimmune and inflammatory diseases; our ability to protect, maintain and enforce our intellectual property protection for vilobelimab and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of vilobelimab and for the finished product Gohibic (vilobelimab); our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved, any commercial sales; if any of our product candidates obtain regulatory approval, our ability to comply with and satisfy ongoing obligations and continued regulatory overview; our ability to comply with enacted and future legislation in seeking marketing approval and commercialization; our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; and our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors or our industry; and the risks, uncertainties and other factors described under the heading “Risk Factors” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this presentation and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Important Notice and Disclaimer Information and Sources Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and InflaRx’s own internal estimates and research. While InflaRx believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Further, while we believe our own internal research is reliable, such research has not been verified by any independent source. Avacopan Data We have not conducted a head-to-head comparison of Avacopan to INF904 in a clinical trial but have compared the published data for Avacopan to data from our Phase 1 clinical trial of INF904. For the purpose of conducting pre-clinical studies (hamster neutropenia study), we synthesized Avacopan and did a side-by-side comparison. While we believe this comparison to Avacopan to be useful and appropriate, the value of this and other comparisons to Avacopan in this presentation may be limited because they are not derived from a head-to-head trial and they are from trials that were conducted under different protocols at different sites and at different times. Without head-to-head data, we are unable to make comparative claims between INF904 and Avacopan. About InflaRx InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, “InflaRx”). InflaRx (Nasdaq: IFRX) is a biotechnology company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize first-in-class, potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.

Speakers Page 4 Prof. Renfeng Guo, M.D. Chief Scientific Officer, Founder, InflaRx Prof. Niels Riedemann, M.D., Ph.D. Chief Executive Officer, Founder, InflaRx Thomas Taapken, Ph.D. Chief Financial Officer, InflaRx Camilla Chong, M.D. Chief Medical Officer, InflaRx Speaker Q&A

INF904: Topline Results from Phase I Multiple Ascending Dose (MAD) Part Page 5 AGENDA safety outcome pk outcome pd outcome study design background and pre-clinical work summary

INF904: Topline Results from Phase I Multiple Ascending Dose (MAD) Part Page 6 AGENDA safety outcome pk outcome pd outcome study design background and pre-clinical work summary

The Complement System and C5a Activation Page 7 Classical Lectin Alternative Complement Pathways Membrane Attack Complex (MAC)triggers lysis of pathogens Antibody binding Mannose binding Foreign surfaces C3 activation C5b-9 = MAC C5-convertases C5b Terminalcomplementactivation C5 Arg751/ Leu752 The extrinsic pathway represents an additional route, outside of the known complement pathways, to cleave C5a from C5 --- C5a acts primarily through C5aR Extrinsic “Pathway” Enzymatic C5 Cleavage inflammation C5aR C5L2 C5a = potent anaphylatoxin C5 Thrombin, Trypsin, Elastase, etc. Scissile bonds other ligands: C3a, ASP, C4a, etc Vilobelimab INF904 X X

Page 8 C5aR, a G-protein-coupled receptor highly expressed on granulocytes and in epithelial cell, mediates the major pathophysiological effects of C5a. Blockade of C5aR showed strong anti-inflammatory effects in numerous pre-clinical disease models in both acute and chronic settings and in clinical research. C5aR antagonists are expected to be stand-alone or adjunct treatments for a variety of inflammatory disorders. One marketed drug candidate only, with a PK/PD profile which could be improved based on the published data of the Phase I clinical trial a. C5aR: a promising drug target aBekker et al. 2016, PLOS ONE 11(10): E0164646 Role of C5aR in pre-clinical and clinical R&D C5aR is a Validated Drug Target for Inflammation Immuno-Dermatology Renal/Vasculitides Respiratory Neurology and related Rheumatology & related CVS & Acute injury Others

Page 9 Improved PK properties with higher plasma trough level (>> 36 ng/mL) to achieve: Improved blocking activity in vivo in humans (>> 50% blocking at 10 nM C5a) = significantly stronger inhibition of neutrophil activation at C5a levels known to be present in diseases. Improved drug strength to allow fewer capsules per dosing and potentially less frequent dosing. 10 nM ≥ 80% inhibition Properties of a best-in-class C5aR antagonist Modified from Bekker et al. (2016, PLoS One; 11(10): e0164646); CCX168 = Avacopan; whole blood ex vivo assay upon 7 days of 2 x qd dosing with Avacopan measuring up-regulation of CD11b on blood neutrophils upon challenge with addition of different levels of recombinant C5a. CD11b is a marker of neutrophil activation known to rise quickly upon interaction of C5a with the C5a receptor. Measurements were taken at 2 hr or 12h upon last dosing (on day 7) and then ex vivo challenge with different doses of C5a. hypothetical curve of an improved inhibitor Improvement of C5aR Inhibition ~50% inhibition

INF904: Pre-clinical Summary INF904 binds to a well-defined allosteric site in C5aR. INF904 has a novel molecular structure. US patent was issued in October 2021; national phases for other select countries (PCT). INF904 facts Page 10 Pre-clinical findings No obvious toxicity findings even in the highest dose groups (rat and monkey; up to 300 mg/kg). High in vitro potency with a desired IC50 (<1nM) in calcium mobilization assay. Higher plasma exposures in several in vivo models when compared to Avacopan*. Increased efficacy in hamster neutropenia model when tested at equivalent dose with an Avacopan-like molecule*. Therapeutic effects in pre-clinical disease models (renal/peritonitis). INF904 binds to allosteric binding site C5aR structure (Source: Nathan Robertson, 2018 Nature) Trp213 (human, primate, hamster) C5a *InflaRx data on file. Avacopan synthesized based on the published structure and publicly available data.

Page 11 INF904 Phase I Study Designs for SAD and MAD 3mg SAD (N=8, in 6:2 ratio) Safety evaluation Safety evaluation Safety evaluation Safety evaluation Safety evaluation 30mg QD MAD N=8 (in 6:2 ratio) Safety evaluation Safety evaluation Single Ascending Dose (SAD) Multiple Ascending Dose (MAD) Footnotes: N= participants per dosing cohort, Ratio for randomization is shown for INF904 : matching Placebo; *3 different capsule strengths tested in a cross-over design 10mg SAD (N=8, in 6:2 ratio) 30mg SAD (N=8, in 6:2 ratio) 60mg* SAD (N=22, in 18:4 ratio) 120mg SAD (N=8, in 6:2 ratio) 240mg SAD (N=8, in 6:2 ratio) 30mg BID MAD N=8 (in 6:2 ratio) 90mg BID MAD N=8 (in 6:2 ratio) Total enrolled: N = 62 Total enrolled: N = 24

INF904: Topline Results from Phase I Multiple Ascending Dose (MAD) Part Page 12 AGENDA safety outcome pk outcome pd outcome study design background and pre-clinical work summary

Page 13 INF904 was found to be well tolerated and resulted in no signals of safety concern in single ascending doses ranging from 3 mg to 240 mg. Overall percentage of Adverse Events (AEs) in placebo group (85.7%) was higher than in active treated subjects (58.3%). AE severity: Mild: 78; Moderate: 9; Severe: 0. No Serious AE (SAE) reported at any dosing level. 1 moderate AE rated as possibly related to placebo (headache) and 2 mild AEs possibly related to study drug (diarrhea, flatulence). 1 subject in cohort 1.4 (60 mg) withdrawn for unrelated AE. INF904 Phase I Study: Safety Results from MAD (and SAD) Part – Primary Objectives INF904 was found to be well tolerated and resulted in no signals of safety concern in multiple ascending doses involving 30 mg QD, 30 mg BID and 90 mg BID. Overall percentage of AEs in placebo group was 83.3% compared to 77.8% in active treated subjects. AE severity: Mild: 52; Moderate: 5; Severe: 0. No SAE reported at any dosing level. 2 AEs, both of mild intensity and both in 1 subject (cohort 3.3/90 mg BID), rated as possibly related to study drug (diarrhea, flatulence). NO subject withdrawn from treatment/study. SAD PART MAD PART

INF904: Topline Results from Phase I Multiple Ascending Dose (MAD) Part Page 14 AGENDA safety outcome pk outcome pd outcome study design background and pre-clinical work summary

INF904 Phase I Study: PK Results from the Multiple Ascending Dose (MAD) Page 15 QD: Once Daily Dosing, BID: Twice Daily Dosing Results are based on interim data analysis INF904 dosing either once daily (QD) or twice daily (BID) exhibits favorable concentration-time profiles (after 14 days dosing) INF904 exposure is directly proportional to dose when comparing 30 mg BID versus the 90 mg BID regimens In BID regimen, accumulation observed (Day 1 to 14) for Cmax and AUC0-12hr average ~ 1.3 and ~1.9-fold The first 90 mg dose achieves greater exposure than seen with Day 14 of the 30 mg BID dosing Dose (Regimen) Day Cmax (ng/mL) ±SD AUC0-12hr (ng x hr/mL) ± SD 30 mg QD 1 233 ± 79 1,615 ± 427 B1 14 284 ± 60 2,609 ± 792 30 mg BID 1 236 ± 97 1,742 ± 648 B2 14 356 ± 84 3,331 ± 821 90 mg BID 1 653 ± 217 4,815 ± 1,993 14 1,028 ± 431 8,962 ± 4,247

INF904: Topline Results from Phase I Multiple Ascending Dose (MAD) Part Page 16 AGENDA safety outcome pk outcome pd outcome study design background and pre-clinical work summary

INF904 – Phase I: Whole Blood PD AnalysisMultiple Ascending Dose (MAD) Part INF904: 30 mg QD INF904: 30 mg BID INF904: 90 mg BID Upon the stimulation with 12.6 nM rhC5a (levels observed in disease state) 24 h 144 h (Day 6) 168 h (Day 7) 312 h (Day 13) 336 h (Day 14) C5a (nM) 30QD 30BID 90BID 30QD 30BID 90BID 30QD 30BID 90BID 30QD 30BID 90BID 30QD 30BID 90BID Blockade (%) 80 94 90 93 95 94 95 97 97 96 92 97 90 95 97 EC50 (nM) 35.6 106.2 145.6 52.4 134.7 160 74.2 149.0 268.2 92.4 126.3 465.7 94.6 110.9 238 *EC50 (nM) is the half maximal effective C5a concentration

INF904: Topline Results from Phase I Multiple Ascending Dose (MAD) Part Page 18 AGENDA safety outcome pk outcome pd outcome study design background and pre-clinical work summary

SummaryTopline Results from INF904 Phase I MAD Study Page 19 Key Outcomes INF904 was found to be well tolerated and with no signals of safety concern in multiple ascending doses ranging from 30mg QD – 90 mg BID. INF904 demonstrated a favorable PK profile with potential to achieve therapeutic exposures (AUC & Cmax) required in chronic immuno-inflammatory diseases. INF904 achieved > 90% C5a blocking potential at C5a concentrations observed in human diseases. INF904 confirms its best-in-class C5aR inhibitor potential within this Phase I multiple ascending dose study

INF904: Next Steps Page 20 Further drug development steps: Introducing developed commercially viable formulation for Phase II clinical program Complete long-term chronic toxicology studies Planning for Phase II clinical studies to be initiated towards end of 2024 Highlights

Winzerlaer Str. 207745 Jena, Germany Email: IR@inflarx.com Tel: +49-3641-508180 Fax: +49-3641-508181 InflaRx N.V. www.inflarx.com

Page 22 Pre-clinical data (previously reported) Appendix SAD data (previously reported)

INF904: Potential Best-in-Class C5aR Inhibitor Plasma Concentration Sampled at 8 hours: INF904 = 538 ng/mL Avacopan-like molecule = 119 ng/mL Page 23 PRE-CLINICAL IN VIVO EFFICACY COMPARISON OF INF904 to AVACOPAN* Inhibition of in vivo neutrophil activation by INF904 compared to Avacopan-like molecule* Source: InflaRx data on file. *Avacopan synthesized based on the published structure and publicly available data. Experiment: Challenge of rodents with C5a leads to neutrophil activation and consequent adherence (sticking) of neutrophils to the endothelial cell wall of vessels = mimicking a neutropenia (vehicle). This effect can be completely inhibited when C5aR activation is blocked. Outcome: INF904 is significantly superior to an identical dose of the Avacopan* in blocking C5aR, leading to an approximate doubling of neutrophil inhibition in vivo in this rodent model. Note: INF904 dosing within this experiment exerts an approx. 4.5-fold higher plasma level 8 h after dosing when compared to the identical dosing with the Avacopan*.

INF904 Phase I Study: PK Results from SAD Part Page 24 In comparison to published data for Avacopan, INF904 is approximately 3-fold higher in Cmax and 10-fold higher in systemic exposure (AUClast) for comparable doses (3, 10, 30 mg) Parameter Unit Dose INF904 Avacopan* AUCinf h.ng/ml 3 mg 285 25 10 mg 1264 130 30 mg 5956 628 AUClast h.ng/ml 3 mg 254 23 10 mg 1117 122 30 mg 5197 557 Cmax ng/ml 3 mg 21.5 9 10 mg 74.8 25 30 mg 289 79 tmax hr 3 mg 3.5 1.2 10 mg 4 1.7 30 mg 5.01 1.7 INF904 240mg INF904 60mg INF904 30mg INF904 120mg Avacopan* 30mg INF904 240mg INF904 60mg INF904 30mg INF904 120mg Source: Bekker et al. (2016, PLoS One; 11(10): e0164646) *Please note: Avacopan data taken from Bekker et al. (2016, PLoS One; 11(10): e0164646) are superimposed in graph for orientation; Avacopan was not included as a comparator in INF904 Phase I study.

Page 25 INF904 was well tolerated in treated healthy volunteers and resulted in no safety signals of concern in single ascending doses ranging from 3mg to 240mg. Overall percentage of adverse events (AEs) in placebo group was higher than in active treated subjects. AE severity: Mild: 81 Moderate: 9 Severe: 0 No serious AE (SAE) reported at any dosing level. 1 moderate AE rated as possibly related to study drug (headache), but subject had received placebo. 1 withdrawn subject in cohort 1.4 (60 mg) for unrelated AE. Highlights INF904 Phase I Study: Safety Results from SAD Part

INF904 Phase I Study: PD Results from SAD Part C5a-mediated CD11b upregulation on neutrophils ex vivo at 24h post dosing Page 26 INF904 blocking activity for C5a-induced neutrophil activation in human plasma achieved set goal and is clearly differentiated from the published blocking activity of the only marketed comparator INF904: In response to 12.64 nM of C5a, ≥ 90% blocking activity was observed in the PD analysis in the dose range of 30-240 mg at the time point of 24-hour post dosing. Avacopan: In response to ~12.64 nM of C5a, approximately 50% blocking activity was observed in the Phase I published data for 30mg dosing at the time point of 12-hour post dosing. (Bekker et al. PLoS One 2016; 11(10): e0164646) 12.6 nM ≥ 90% blockade C5a (nM) INF904 (Blocking Activity % vs Placebo) C5a (nM) 3mg 10mg 30mg 60mg 120mg 240mg 12.6 9.6 74.7 91.5 95.7 95.2 98.7

INF904 confirms its best-in-class C5aR inhibitor potential within this Phase I single ascending dose study Summary Topline Results from INF904 Phase I SAD Study Page 27 Key Outcomes INF904 was well tolerated in treated healthy volunteers and resulted in no safety signals of concern in single ascending doses ranging from 3mg to 240mg. INF904 demonstrated a favorable PK profile: Tmax 6 hours, dose proportional exposure from 3 to 240mg. INF904 demonstrated a strong C5a blocking potential at C5a concentrations observed in human diseases. INF904 can be formulated with a higher drug strength of 30mg per capsule vs. 10mg per capsule for the marketed comparator.